Jeffrey V. Lazarus

2 days ago | nature.com | Jeffrey V. Lazarus |Paul Brennan |Philippa Matthews |Juan Vaz |Scott Isaacs |Michael Roden | +6 more

Reducing the stigma and discrimination that people living with liver conditions experience requires rethinking how diagnoses, diseases, etiologies and circumstances are perceived — a shift that begins with the language used to name and describe them. You have full access to this article via your institution.

Mar 7, 2025 | digitalcommons.library.tmc.edu | Christopher Byrne |Mary E. Rinella |Jeffrey V. Lazarus |Vlad Ratziu

KeywordsMale, Female, Humans, Non-alcoholic Fatty Liver Disease, Delphi Technique, Hepatomegaly, Surveys and QuestionnairesAbstractThe principal limitations of the terms NAFLD and NASH are the reliance on exclusionary confounder terms and the use of potentially stigmatising language. This study set out to determine if content experts and patient advocates were in favor of a change in nomenclature and/or definition. A modified Delphi process was led by three large pan-national liver associations.

Mar 7, 2025 | digitalcommons.library.tmc.edu | Jeffrey V. Lazarus |Diana Romero |Christopher J. Kopka |Salim Abdool Karim

KeywordsHumans, COVID-19, Delphi Technique, Government, Pandemics, Public Health, International Cooperation, Organizations, COVID-19 Vaccines, Communication, Health Education, Health Policy, Public OpinionAbstractDespite notable scientific and medical advances, broader political, socioeconomic and behavioural factors continue to undercut the response to the COVID-19 pandemic1,2.

Apr 19, 2024 | nature.com | Jeffrey V. Lazarus

The US Food and Drug Administration (FDA) has approved the first drug, resmetirom, for metabolic dysfunction-associated steatohepatitis (MASH), but much work remains for the industry, practitioners and health systems so that this approval will benefit all patients.

Apr 12, 2024 | inserm.hal.science | Jeffrey V. Lazarus |Henry E Mark |Alina Allen

Article Dans Une Revue Hepatology Année : 2023 A global action agenda for turning the tide on fatty liver disease Origine : Publication financée par une institution Licence : CC BY - Paternité inserm-04544391 , version 1 (12-04-2024) Jeffrey V Lazarus, Henry E Mark, Alina M Allen, Juan Pablo Arab, Patrizia Carrieri, et al.. A global action agenda for turning the tide on fatty liver disease. Hepatology, 2023, 79, pp.502 - 523.